Overview / Abstract: |
In this activity, Steven Pipe, MD and Guy Young, MD introduce the unmet medical needs experienced by patients with hemophilia. They review the mechanisms of action and most recent clinical trial data for the most advanced substitution therapies (emicizumab), hemostatic rebalancing agents (concizumab, marstacimab, and fitusiran), and gene therapies. The faculty also discuss how approval of these treatments could affect patient care, and the questions that need to be addressed in ongoing phase 3 clinical trials for them to enter clinical practice. |
Expiration |
Jul 29, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME |
Format |
Online |
Credits / Hours |
1.0 |
Accreditation |
AMA PRA Category 1 Credits™, ANCC |
Presenters / Authors / Faculty |
Steven Pipe, MD Guy Young, MD |
Activity Specialities / Related Topics |
Emergency Medicine, Hematology, Oncology / Cancer / Radiation Therapy, Pediatrics |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent medical education grant from Novo Nordisk, Inc. |
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Hemophilia A, Hemophilia B, Hemophilia with inhibitors, Nonfactor substitution therapy, Hemostatic rebalancing, Extrinsic clotting pathway Emerging therapies Free CE CME |